Outcomes following salvage autologous stem cell transplant (ASCT2) vs low dose alkylating consolidation therapy following bortezomib-containing re-induction for relapsed multiple myeloma (MM) may be dependent on age and symptomatic status initiation of re-induction: results from the myeloma X (intensive) trial.
Authors
Ashcroft, JCairns, D
Williams, C
Hockaday, A
Cavenagh, J
Snowden, J
Parrish, C
Yong, K
Cavet, James
Hunter, H
Bird, J
Pratt, G
Chown, S
Heartin, E
O'Connor, S
Brown, J
Morris, C
Cook, G
Affiliation
Mid-Yorkshire Hospitals NHS Trust/Univeristy of Leeds, WakefieldIssue Date
2015